DE2328059A1 - Pharmazeutische zubereitungen, enthaltend gefaesserweiternde oder gefaessregulierende mittel und substanzen, die auf das anhaften und die zusammenballung der blutplaettchen einwirken - Google Patents
Pharmazeutische zubereitungen, enthaltend gefaesserweiternde oder gefaessregulierende mittel und substanzen, die auf das anhaften und die zusammenballung der blutplaettchen einwirkenInfo
- Publication number
- DE2328059A1 DE2328059A1 DE19732328059 DE2328059A DE2328059A1 DE 2328059 A1 DE2328059 A1 DE 2328059A1 DE 19732328059 DE19732328059 DE 19732328059 DE 2328059 A DE2328059 A DE 2328059A DE 2328059 A1 DE2328059 A1 DE 2328059A1
- Authority
- DE
- Germany
- Prior art keywords
- preparations according
- salts
- aspirin
- aggregation
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000126 substance Substances 0.000 title claims description 7
- 230000002776 aggregation Effects 0.000 title claims description 6
- 239000003795 chemical substances by application Substances 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 230000002792 vascular Effects 0.000 title claims description 4
- 238000004220 aggregation Methods 0.000 title claims description 3
- 230000001105 regulatory effect Effects 0.000 title claims description 3
- 210000001772 blood platelet Anatomy 0.000 title claims 3
- 238000002360 preparation method Methods 0.000 claims description 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 8
- 229940124549 vasodilator Drugs 0.000 claims description 8
- 239000003071 vasodilator agent Substances 0.000 claims description 8
- SWNNLZURDOQIQO-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-acetyloxybenzoate Chemical group CN(C)CCOC(=O)C1=CC=CC=C1OC(C)=O SWNNLZURDOQIQO-UHFFFAOYSA-N 0.000 claims description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 3
- 241000863486 Vinca minor Species 0.000 claims description 3
- 238000005054 agglomeration Methods 0.000 claims description 3
- GRTOGORTSDXSFK-UHFFFAOYSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-UHFFFAOYSA-N 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 229960001789 papaverine Drugs 0.000 claims description 3
- ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002726 vincamine Drugs 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000219 Sympatholytic Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 229960003133 ergot alkaloid Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000000948 sympatholitic effect Effects 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 description 6
- 238000011835 investigation Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 2
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- -1 salicylic acid compound Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 201000004553 aspirin allergy Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- DEQITUUQPICUMR-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 DEQITUUQPICUMR-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- SPXACGZWWVIDGR-SPZWACKZSA-N dihydroergocristine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 SPXACGZWWVIDGR-SPZWACKZSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003422 vasoregulatory effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7220390A FR2187315B1 (enExample) | 1972-06-05 | 1972-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2328059A1 true DE2328059A1 (de) | 1974-01-03 |
Family
ID=9099788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732328059 Ceased DE2328059A1 (de) | 1972-06-05 | 1973-06-01 | Pharmazeutische zubereitungen, enthaltend gefaesserweiternde oder gefaessregulierende mittel und substanzen, die auf das anhaften und die zusammenballung der blutplaettchen einwirken |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE800462A (enExample) |
| DE (1) | DE2328059A1 (enExample) |
| FR (1) | FR2187315B1 (enExample) |
| GB (1) | GB1435923A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118064361A (zh) * | 2024-01-31 | 2024-05-24 | 广州市微米生物科技有限公司 | 一种用于减缓离体血小板自发激活的添加剂及其制备方法和应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2319359A1 (fr) * | 1975-07-31 | 1977-02-25 | Parcor | Medicament nouveau a base de vincanol et d'acide acetylsalicylique |
| US4511557A (en) * | 1981-08-24 | 1985-04-16 | Gauri Kailash Kumar | Pharmaceutical composition |
| ATE172183T1 (de) * | 1992-07-30 | 1998-10-15 | Cal Int Ltd | Ester und kombinationen von einem organischen nitrat und einem salicyclat |
| FR2852844A1 (fr) * | 2003-03-31 | 2004-10-01 | Michel Thiebault Horvilleur | Composition pharmaceutique destinee a la prevention des accidents cardiovasculaires |
-
1972
- 1972-06-05 FR FR7220390A patent/FR2187315B1/fr not_active Expired
-
1973
- 1973-05-31 GB GB2591173A patent/GB1435923A/en not_active Expired
- 1973-06-01 DE DE19732328059 patent/DE2328059A1/de not_active Ceased
- 1973-06-05 BE BE131886A patent/BE800462A/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118064361A (zh) * | 2024-01-31 | 2024-05-24 | 广州市微米生物科技有限公司 | 一种用于减缓离体血小板自发激活的添加剂及其制备方法和应用 |
| CN118064361B (zh) * | 2024-01-31 | 2025-03-14 | 广州市微米生物科技有限公司 | 一种用于减缓离体血小板自发激活的添加剂及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1435923A (en) | 1976-05-19 |
| BE800462A (fr) | 1973-10-01 |
| FR2187315B1 (enExample) | 1975-06-20 |
| FR2187315A1 (enExample) | 1974-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69635959T2 (de) | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme | |
| DE69022876T2 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| DE2624025C2 (enExample) | ||
| DE69305335T2 (de) | Pharmazeutische zubereitung und verfahren für ihre herstellung | |
| DE2903558A1 (de) | Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung | |
| DD216163A5 (de) | Verfahren zur herstellung eines oral verabfolgbaren cefaclor-praeparates mit verzoegerter wirkstoffabgabe | |
| DE3338995A1 (de) | Bilobalid enthaltende arzneimittel | |
| DE3390114C2 (enExample) | ||
| DE2638507A1 (de) | Arzneimittel mit anabolischer wirksamkeit | |
| DE69323759T2 (de) | Verwendung von toremifene für die behandlung von sle | |
| DE69005860T2 (de) | Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln. | |
| DE3603564A1 (de) | Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung | |
| EP0214620B1 (de) | Transdermale Applikationsform von Diltiazem | |
| DE2343218C2 (de) | Furosemid enthaltende Pellets | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE3035494A1 (de) | Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE10228680A1 (de) | Grundlage für transdermale Formulierungen (PTF) | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| EP0207193A2 (de) | Synergistische Kombination von Flupirtin und 4-Acetamido-phenol | |
| DE3212909C2 (enExample) | ||
| DE69304266T2 (de) | Zusammensetzung enthaltend Dibucaine-Hydrochlorid, ein Salicylat, Calciumbromid und ein antiphlogistisches steroid zur Schmerzbekämpfung | |
| DE3741414A1 (de) | Verwendung von calciumantagonisten bei der behandlung von entzuendungen und oedemen | |
| US3071508A (en) | Compositions for oral administration in unit dosage form for prophylaxis and treatment of poison ivy and poison sumac dermatitis | |
| DE2707763A1 (de) | Verwendung von vincamin zur behandlung von kreislauferkrankungen des gehirns und dazu geeignetes arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8131 | Rejection |